NEW YORK – Stanford Medicine’s Center for Inherited Cardiovascular Disease transitioned this week to clinical whole-genome sequencing for all of its in-house gene panel tests covering different classes of inherited conditions.
By implementing a whole-genome backbone for these assays now, the center believes it can continue to offer comprehensive, clinically validated testing, while also making it easier to expand its offerings over time and to reflex to broader analyses if an initial test fails to identify the cause of a patient’s disease.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
